Back to top
more

10x Genomics (TXG)

(Real Time Quote from BATS)

$21.31 USD

21.31
1,255,362

+1.66 (8.45%)

Updated Aug 13, 2024 03:04 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 250)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for TXG

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for 10x Genomics falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 389 433 588 680 424
Receivables 115 104 85 51 33
Notes Receivable 0 0 0 0 0
Inventories 74 82 60 30 15
Other Current Assets 19 17 14 13 8
Total Current Assets 596 635 748 774 481
Net Property & Equipment 280 289 169 73 49
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 21 27 30 0 0
Deposits & Other Assets 3 7 11 35 76
Total Assets 965 1,029 1,019 929 606
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 16 22 17 5 13
Current Portion Long-Term Debt 0 0 0 0 10
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 87 92 83 103 37
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 13 8 5 4 3
Total Current Liabilities 127 131 110 118 63
Mortgages 0 0 0 0 0
Deferred Taxes/Income 9 0 0 0 17
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 20
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 4 6 14 15 86
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 224 223 201 190 186
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 2,026 1,839 1,681 1,544 682
Retained Earnings -1,284 -1,029 -863 -805 -262
Other Equity 0 -4 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 741 806 818 739 420
Total Liabilities & Shareholder's Equity 965 1,029 1,019 929 606
Total Common Equity 741 806 818 739 420
Shares Outstanding 119.10 115.20 112.50 108.40 96.20
Book Value Per Share 6.22 6.99 7.27 6.82 4.37

Fiscal Year End for 10x Genomics falls in the month of December.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents 380 372 389 357 393
Receivables 91 91 115 104 88
Notes Receivable 0 0 0 0 0
Inventories 88 83 74 81 84
Other Current Assets 20 21 19 20 19
Total Current Assets 579 567 596 562 583
Net Property & Equipment 263 269 280 285 285
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 21 21 21 26 27
Deposits & Other Assets 5 3 3 6 24
Total Assets 930 923 965 949 990
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable 0 0 0 0 0
Accounts Payable 21 20 16 19 23
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 63 63 87 65 56
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 16 14 13 11 9
Total Current Liabilities 111 109 127 105 98
Mortgages 0 0 0 0 0
Deferred Taxes/Income 11 10 9 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 5 4 10 8
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 206 204 224 203 196
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 2,107 2,064 2,026 1,981 1,937
Retained Earnings -1,382 -1,344 -1,284 -1,235 -1,142
Other Equity 0 0 0 -1 -1
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 724 719 741 745 793
Total Liabilities & Shareholder's Equity 930 923 965 949 990
Total Common Equity 724 719 741 745 793
Shares Outstanding 119.17 119.17 119.10 117.40 116.10
Book Value Per Share 6.08 6.03 6.22 6.35 6.83